To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

Merck shares dipped 0.8% on June 2 from $76.84 to $76.25, then rose nearly 3% over two days to $78.27 on Wednesday before dipping another 0.8% to $77.67 on Thursday, followed by a 1.6% increase ...

2. Enhance SpringWorks’ global credibility and potentially facilitate approvals in other international markets. 3. Generate additional revenue to support ongoing research and development efforts. 4.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y ...

Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely ...

Merck gets lift from U.S. patent office in battle over injectable form of Keytruda Dispute with Halozyme Therapeutics could affect plans to extend its franchise product Manage alerts for this article ...